Co., Ltd. ("LongBio" or the "Company"), a Phase III-stage biotech company focused on the R&D of innovative antibody and fusion protein drugs for allergies and complement-mediated diseases, announced ...
Over the past few years it has become clear that, in addition, bacteria can escape recognition by the complement system through the actions of cell-surface or secreted proteins 1,2. After their ...